BIVI

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined its evolving approach to Parkinson’s disease, with CEO Cuong Do highlighting the company’s focus on neuroinflammation and insulin resistance as key drivers of the condition. Speaking to Proactive, Do explained that while Parkinson’s is commonly associated with dopamine deficiency and loss of muscle control, this represents only part of the disease mechanism. He said the company believes inflammation in the brain leads to insulin resistance, which in turn deprives neurons of the energy they need to function. Do described the process by noting that inflammation “acts like rust on that lock,” preventing insulin from enabling glucose uptake into cells. BioVie’s lead drug candidate, bezisterim, is designed to target these underlying mechanisms. According to Do, clinical data has shown that the therapy can reduce neuroinflammation and reverse insulin resistance. He added that this may restore energy flow to neurons and improve their function. The company has already generated encouraging results from an earlier clinical study in which bezisterim was used alongside levodopa, the current standard of care. In that trial, patients receiving the combination demonstrated improved muscle control compared to those treated with levodopa alone, providing what Do described as “human proof of concept.” BioVie is now advancing a second study evaluating bezisterim as a standalone treatment in patients at an earlier stage of Parkinson’s disease. The trial has enrolled 60 participants, randomized between placebo and treatment arms. The objective is to demonstrate improvements not only in motor symptoms but also in non-motor aspects such as sleep disturbances, anxiety, and depression. Do indicated that the trial is fully enrolled and that the company expects to report topline data before the end of June. This upcoming readout represents a key catalyst, as positive results could support the broader use of bezisterim across different stages of Parkinson’s disease.